Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Serious adverse events ‐ remission or mild disease (8 weeks) · IBD patients
It is very uncertain whether IV iron isomaltoside changes serious adverse events ‐ remission or mild disease (8 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients
It is very uncertain whether IV iron sucrose changes serious adverse events ‐ mild to moderate disease (20 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (12 weeks) · IBD patients
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (12 weeks) compared with IV iron sucrose (very low certainty).
1 finding from 1 review
Serious adverse events ‐ active or inactive disease (14 days) · IBD patients
It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).
1 finding from 1 review
Serious adverse events ‐ disease activity not stated (12 weeks) · IBD patients
1 finding from 1 review
Serious adverse events ‐ mild disease to quiescent (up to 52 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Serious adverse events · IBD patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · IBD patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · participants with quiescent IBD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · participants with quiescent IBD
1 finding from 1 review
Serious adverse events · participants with quiescent IBD
1 finding from 1 review
Serious adverse events (12 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events (12 weeks) compared with IV ferric carboxymaltose (very low certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · participants with quiescent IBD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · participants with quiescent IBD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found